OPKO Health, Inc. Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- OPKO Health, Inc. treasury stock, value, acquired, cost method for the quarter ending 2026-06-30 was $8.40M.
- OPKO Health, Inc. treasury stock, value, acquired, cost method for the quarter ending 2026-03-31 was $4.80M.
- OPKO Health, Inc. treasury stock, value, acquired, cost method for fiscal 2024 was $40.20M.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2026-06-30 | $8.40M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2026-08-28 | |
| 2026-03-31 | $4.80M 10-Q/A · filed 2026-08-28 | |
| 2025-12-31 | $87.20M 10-Q/A · filed 2026-08-28 | |
| 2024-12-31 | $40.20M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |